Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic
options. The mechanisms underlying LMS development, including clinically actionable …

Leiomyosarcomas (LMS) are genetically heterogeneous tumors differentiating along smooth
muscle lines. Currently, LMS treatment is not informed by molecular subtyping and is …

Leiomyosarcoma (LMS) is a soft tissue tumor with a significant degree of morphologic and
molecular heterogeneity. We used integrative molecular profiling to discover and …

Purpose: Leiomyosarcoma is a malignant neoplasm with smooth muscle differentiation.
Little is known about its molecular heterogeneity and no targeted therapy currently exists for …

Leiomyosarcoma is an aggressive mesenchymal malignancy and represents one of the
most common subtypes of soft tissue sarcomas. It is characterized by significant disease …

Leiomyosarcoma is a malignant mesenchymal tumor composed of cells showing smooth
muscle differentiation. This tumor usually occurs in middle-aged or older adults, and forms a …

Background Soft‐tissue sarcomas (STS) describe a heterogeneous group of mesenchymal
tumors with limited treatment options. Targeted therapies exist for BRCA1/2 gene alterations …

Liposarcoma (LPS) is the most common type of soft tissue sarcoma accounting for 20% of all
adult sarcomas. Due to absence of clinically effective treatment options in inoperable …

Leiomyosarcoma - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe
PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog Tech …

Soft-tissue sarcomas, which result in approximately 10,700 diagnoses and 3,800 deaths per
year in the United States, show remarkable histologic diversity, with more than 50 …